Activity

  • NipperCat posted an update in the group The WeHeal Welcome Community

    Are you aware of how much we are aiding environmental pollution with our discarded metal tooth fillings! WOW!
    (See also — https://iaomt.org/wp-content/uploads/Comprehensive-Review-Dental-Mercury.pdf)

  • NipperCat posted an update in the group The WeHeal Welcome Community

    Be good to yourself and stop eating all that sugar! Attention: sugar derivatives and polysaccharides (e.g., maltodextrin) are in sugar substitutes, some vital pills, and many other foods. Read all labels carefully be fore buying anything. Fresh fruit and veggies are the way to eat well!

  • NipperCat posted an update in the group The WeHeal Welcome Community

    Be good to yourself and stop eating all that sugar! Attention: sugar derivatives and polysaccharides (e.g., maltodextrin) are in sugar substitutes, some vital pills, and many other foods. Read all labels carefully be fore buying anything. Fresh fruit and veggies are the way to eat well!

  • Eric Drew posted an update in the group Ovarian Cancer Advocate Network

    This is a recent treatment consultation we arranged for a stage 4 ovarian cancer patient. Bottom line, the latest most effective treatments seem to be a combination of immune therapy with a PARP inhibitor therapy. https://en.wikipedia.org/wiki/PARP_inhibitor – Get your free consultation on the WeHeal home page to find the most advanced treatments available for your case.

    From your Caris reports, I see that your tumors are PD-L1 positive. It would make sense to try checkpoint immune inhibitors if you haven’t already had them.

    Single-agent immunotherapy such as nivolumab (anti-PD-1) has demonstrated a modest response rate of 15% in PD-L1–positive platinum-resistant ovarian cancer. Recently, results of KEYNOTE-100 (NCT02674061) study showed that the overall response rate (ORR) with pembrolizumab (anti-PD-1) in patients with advanced recurrent ovarian cancer was 9% and was higher in patients with PD-L1 expression: 14% with a combined positive score ≥1 and 25% with a composite positive score of ≥10.

    Since you also carry the BRCA1 mutation, it would also make sense to investigate PARP inhibitors in combination with immunotherapy. For example, Niraparib (a PARP inhibitor), has shown efficacy in patients with platinum-resistant/refractory ovarian cancer when in combination with pembrolizumab (anti-PD-1). Data from the recurrent ovarian cancer cohort of a recent trial showed an objective response rate of 25% in the 60 evaluable patients. The combination was also well-tolerated by patients. Please see: https://www.onclive.com/conference-coverage/sgo-2018/pembrolizumab-plus-niraparib-shows-promise-in-ovarian-cancer

    Additionally, findings from the phase II MEDIOLA trial evaluating the combination of the PARP inhibitor olaparib and the anti-PD-L1 inhibitor durvalumab (Imfinzi) demonstrated a 72% ORR in patients with relapsed, platinum-sensitive, BRCA-mutated ovarian cancer. So, this approach of combining of anti-PD-1/L1 immune agent with another PARP inhibitor may be suitable for you. Please discuss this option with your treating team.

  • HelloitsB posted an update in the group The WeHeal Welcome Community

    We support the right of every individual to choose whether or not to participate in vaccinations, free from threats and coercive strategies, and with informed consent as to the pros, cons, and current lack of scientific integrity supporting them. The Association of American Physicians and Surgeons agrees and has issued the following statement (link to their website) —

  • NipperCat posted an update in the group The WeHeal Welcome Community

    Important information for all of us to consider!